Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: A multicenter, double-masked study

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 6, 1997, Pages 331-342

  Viskoper, Reuven J ^a   Compagnone, Daniele ^b   Dies, Reiner ^b   Zilles, Peter ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Knoll AG   (Germany)

Author keywords

Essential hypertension; Resistant hypertension; Verapamil SR trandolapril combination therapy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

EID: 0030745183     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80092-6     Document Type: Article

References (24)

1. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int. 1992;41:912-919.
2. Bakris GL. Hypertension in diabetic patients. Am J Hypertens. 1993;6(Suppl 4):140S-147S.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEJM. 1991;325:293-301.
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. NEJM. 1992;327:685-691.
5. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results on the Survival and Ventricular Enlargement Trial. NEJM. 1992;327:669-677.
6. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295-1297.
7. Lithell H. Insulin resistance and cardiovascular drugs. Clin Exp Hypertens. 1992;14:151-162.
8. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens. 1993;11:905-918.
9. James IM. Which antihypertensive? Br J Clin Pract. 1990;44:102-105.
10. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
11. Messerli FH. Combination therapy in hypertension. J Hum Hypertens. 1992;6(Suppl 2):S19-S21.
12. Midbø K, Lauve O, Hals O. No metabolic side effects of long-term treatment with verapamil in hypertension. Angiology. 1988;39:1025-1029.
13. Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994;48:71-90.
14. de Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs. A double-blind, placebo controlled parallel group study. J Hypertens. 1997; 15:87-91.
15. Frohlich ED, Grim C, Labarthe DR, et al. Recommendations for human blood pressure determination by sphygmomanometers. Hypertension. 1988;11:210A-222A.
16. Viskoper RJ, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertension. Curr Ther Res. 1997;58:343-351.
17. Harpat SR, Kates RE. High performance liquid Chromatographic analysis of verapamil. J Chromatogr. 1980;181:484-489.
18. Tremblay D, Mouren M. Methodes radioimmunologiques de dosage du trandolapril (RU 44570) et de son metabolite diacide (RU 44403) dans le plasma humain. Ref 89/1532/CN, Roussel-Uclaf, Romainville, France.
19. Snappin SM. Evaluating the efficacy of a combination therapy. Stat Med. 1987;6:657-665.
20. Bainbridge AD, MacFadyen RJ, Stark S, et al. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension. Br J Clin Pharmacol. 1993;36:323-330.
21. Bild D, Teutsch SM. The control of hypertension in persons with diabetes: A public health approach. Public Health Rep. 1987;102:522-529.
22. Ritz E. Hypertension and nephropathy in type II diabetes. Proc R Coll Physicians Edin. 1996;26:374-383.
23. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996;125:204-210.
24. Reid JL. First-line and combination treatment for hypertension. Am J Med. 1989;86(Suppl 4A):2-5.